Loss of 11β-HSD2 protein in AR-expressing LAPC4, VCaP and MDA-PCa-2b prostate cancer cell lines (but not an AR-negative prostate cancer cell line [Figure 2—figure supplement 1A]) was observed with enzalutamide treatment, while no consistent effect on 11β-HSD1 was detectable (Figure 2A–D and Figure 2—figure supplement 1B). The gene discussed is AR; the disease is prostate cancer.